The purpose of AdaptResponse was to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).
Results presented at the European Heart Rhythm Association (EHRA) 2023. Publication pending.
Link to ClinicalTrials.gov for study description.
Other resources:
View the Radcliff Cardiology presentation recorded at EHRA 2023.
Press release: AdaptResponse Study Results Presented as Late Breaking Science at European Heart Rhythm Association (EHRA) 2023, Medtronic News, April 17, 2023